|Articles|October 1, 2001
- Pharmaceutical Executive-10-01-2001
- Volume 0
- Issue 0
PBMs: Merck-Medco in the Hot Seat
Author(s)Andra Brichacek
Franklin Lakes, New Jersey-Merck’s pharmacy benefit arm, Merck-Medco, is under fire for switching patients to more expensive pharmaceuticals.
Advertisement
Articles in this issue
about 24 years ago
National Crisis Supercedes Coverage Debateabout 24 years ago
National Crisis Supercedes Coverage Debateabout 24 years ago
A Five-Year Forecast: Clear Seas Ahead?about 24 years ago
Weak Bones, Strong Marketabout 24 years ago
Approvals: Novartis’ Silver Liningabout 24 years ago
Pfizer and others Pitch Inabout 24 years ago
Oncology: EMEA Approval Lagsabout 24 years ago
Illegal Sales in Indiaabout 24 years ago
Health Plan Premiums: Pharma Takes the Blameabout 24 years ago
Little Elan Becomes a Big DealNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Bayer’s Lynkuet as First Dual Neurokinin Antagonist for Menopausal Hot Flashes
2
TrumpRx and the Dawn of Direct-to-Consumer Commercialization
3
FDA Approves Blenrep for Treatment of Replapsed/Refractory Multiple Myeloma
4
Pharmaceutical Executive Daily: TrumpRx's Implication on DTC Commercialization
5
